DON'T BUY

A horror show with three CEOs in the last 14 months. Even before COVID, this was in bad shape. It was oversold during the spring, but rebounded partly by June. Then the US sunbelt got hit with the second wave, which pushed down this stock. It's a tricky one. It's cheap, selling at 4x next year's estimated earnings, but estimates for it have fallen. It's a value trap. A COVID vaccine will boost this stock, but there are better ways to play the recovery (i.e. Visa or Paypal).

BUY ON WEAKNESS
They make precision control systems for army aircraft, satellites and missiles. Defence spending isn't a target in the current US election. Biden isn't Sanders. Moog is a longtime winner. It was oversold in March and has partially recovered, because 19% of their business comes from the now-weak commercial aircraft business. Moog could work with the recovery. Moog is a solid industrial innovator with a fine track record. They will emerge stronger. Wait for a better price during this volatile September.
BUY

FedEx reports on Tuesday and should deliver a strong upside, given that e-commerce is on fire. Tailwinds include a Christmas surcharge and overseas strength, including China. Has long liked this. United Parcel is also a buy.

BUY
Reports next Tuesday and benefits from strong e-commerce trend. Five analysts have raised their targets on Adobe in the last five days. It could surprise to the upside given stay/work-at-home. Should have a strong 2021.
PARTIAL BUY
Had a justified huge move up, but has pulled back a lot. He likes it as current levels. Some may some the head-and-shoulders chart will go down, but he feels it'll hold the trendline.
COMMENT

It IPOs next week and is a cloud-based data warehousing company. Berkshire Hathaway and Salesforce will each buy $250 million of stock. The CEO has a great track record in Silicon Valley; Snowflake is the CEO's third company he's taken public. He sees a lot of demand in Snowflake, so should IPO well. He's conflicted, because the IPO may be too red hot and overbought. He'll know more about this company next week.

BUY
Terrific managers. Down 8% this year so it's a good time to add or enter.
DON'T BUY
A tiny company and speculative. Some months ago, they had a tired, but profitable portfolio of generic and profitable drugs that produced a stream of cash. They invested that cash to treat droopy eyelid, with a goal to be a less-generic drug company and more branded. Then they tested an MS-related drug, but shelved it which hurt the stock. Two months, the FDA approved the droopy eyelid drug which pushed the stock higher. Then they made a secondary offering which didn't meet demand and the stock pulled back.
DON'T BUY
A tiny company and speculative. Some months ago, they had a tired, but profitable portfolio of generic and profitable drugs that produced a stream of cash. They invested that cash to treat droopy eyelid, with a goal to be a less-generic drug company and more branded. Then they tested an MS-related drug, but shelved it which hurt the stock. Two months, the FDA approved the droopy eyelid drug which pushed the stock higher. Then they made a secondary offering which didn't meet demand and the stock pulled back.
BUY
Their speciality is IP phones and they have been doing well. Earnings will almost double from 4 cents to 8 cents, with further doubling in 2022. P/E is at 29x for 2021. If they are able to deliver it, the stock is attractively priced.